117642-16-7

Usage

Uses

Used in Pharmaceutical Applications:
2-AMINO-4,7-DIHYDRO-5H-THIENO[2,3-C]PYRAN-3-CARBOXYLIC ACID ETHYL ESTER is used as a NDMA receptor function inhibitor for its ability to modulate the activity of NDMA receptors, which play a crucial role in various physiological processes and conditions. By inhibiting these receptors, 2-AMINO-4,7-DIHYDRO-5H-THIENO[2,3-C]PYRAN-3-CARBOXYLIC ACID ETHYL ESTER may have potential therapeutic applications in treating conditions related to NDMA receptor dysfunction.
Used in Research and Development:
In the field of scientific research, 2-AMINO-4,7-DIHYDRO-5H-THIENO[2,3-C]PYRAN-3-CARBOXYLIC ACID ETHYL ESTER serves as a valuable tool for studying the function and role of NDMA receptors in cellular processes. It can be used to investigate the mechanisms underlying receptor activation and inhibition, as well as to develop new drugs targeting these receptors for various therapeutic purposes.
Used in Drug Design and Synthesis:
The unique structure of 2-AMINO-4,7-DIHYDRO-5H-THIENO[2,3-C]PYRAN-3-CARBOXYLIC ACID ETHYL ESTER makes it a promising candidate for drug design and synthesis. Researchers can use 2-AMINO-4,7-DIHYDRO-5H-THIENO[2,3-C]PYRAN-3-CARBOXYLIC ACID ETHYL ESTER as a starting point to develop new drugs with improved efficacy, selectivity, and safety profiles by modifying its structure to optimize its interaction with NDMA receptors.
Used in Neuropharmacology:
In the field of neuropharmacology, 2-AMINO-4,7-DIHYDRO-5H-THIENO[2,3-C]PYRAN-3-CARBOXYLIC ACID ETHYL ESTER is used as a research compound to study the role of NDMA receptors in the central nervous system. Understanding the interaction between 2-AMINO-4,7-DIHYDRO-5H-THIENO[2,3-C]PYRAN-3-CARBOXYLIC ACID ETHYL ESTER and NDMA receptors can provide insights into the development of novel therapeutic strategies for neurological disorders associated with NDMA receptor dysfunction.

Upstream product

• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 105-56-6 ethyl 2-cyanoacetate 
• 33451-54-6 ethyl 2-cyano-2-(dihydro-2H-pyran-4(3H)-ylidene)acetate 

Downstream Products

• 923010-75-7 2-amino-4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acid ester 
• 1415149-93-7 C₂₁H₁₉F₅N₂O₃S 
• 1415149-87-9 C₁₉H₁₅F₅N₂O₃S 
• 1415149-83-5 C₂₀H₁₉F₃N₂O₅S 
• 1415149-48-2 C₁₉H₁₈Cl₂N₂O₄S 
• 1415149-81-3 C₂₀H₁₉F₃N₂O₄S 
• 1415149-77-7 C₂₁H₂₃F₃N₂O₅S 
• 1415149-75-5 C₂₁H₂₃F₃N₂O₄S 
• 1415149-71-1 C₁₉H₁₉F₃N₂O₅S 
• 1415149-69-7 C₁₉H₁₉F₃N₂O₄S 
• 1415149-66-4 C₂₀H₁₉F₃N₂O₄S 
• 1415149-47-1 C₁₉H₁₈Cl₂N₂O₄S 
• 1415149-64-2 C₂₁H₂₁F₃N₂O₄S 
• 1415149-63-1 C₂₁H₂₁F₃N₂O₃S 

Relevant academic research and scientific papers

Efficient three-component Gewald reactions under Et3N/H 2O conditions

In a medium consisting of triethylamine and water, methylene ketones undergo room temperature Gewald reactions with elemental sulfur and ethyl cyanoacetate (or malononitrile) to yield 2 aminothiophene derivatives efficiently within short time periods. Because of the high polarity of the medium, products precipitate in the reaction mixtures spontaneously. This makes isolation of the products easy by simple filtration and avoids cumbersome chromatographic separations. Mechanistic studies suggest that the reactions proceed via a Knoevenagel condensation pathway(equation presented). 2013

Synthesis and bioactivities of novel bicyclic thiophenes and 4,5,6,7-tetrahydrothieno[2,3-c]pyridines as inhibitors of tumor necrosis factor-alpha (TNF-alpha) production.

We synthesized bicyclic thiophenes and 4,5,6,7-tetrahydrothieno[2,3-c]pyridine derivatives, and evaluated for their ability to inhibit LPS-stimulated production of TNF-alpha. Several compounds revealed excellent in vivo activity. Furthermore, an effective compound was found in adjuvant-induced arthritic model (AIA) of rat.

An efficient one-pot synthesis of substituted 2-aminothiophenes via three-component gewald reaction catalyzed by l -proline

An efficient one-pot procedure for the direct catalytic synthesis of substituted 2-aminothiophenes catalyzed by l-proline under mild reaction conditions has been developed. A variety of functionalized 2-aminothiophene scaffolds were assembled in high yields by this catalytic protocol. Low catalyst loading, simple procedure, and high yields are the important attributes of this methodology.

Aqueous DABCO, an efficient medium for rapid organocatalyzed Knoevenagel condensation and the Gewald reaction

In the presence of water and 1,4-diazabicyclo[2.2.2]octane, several aldehydes and cyclic ketones underwent efficient Knoevenagel condensation with malononitrile and ethyl cyanoacetate to produce the respective α.β-unsaturated systems within fairly short time periods. As a result, high yields of conjugated products were easily obtained. Products could be engaged in a Gewald reaction, either stepwise or in situ, to produce efficiently their respective 2-aminothiophenes within 4-7 h. TUeBITAK.

A Novel Small Molecular Prostaglandin Receptor EP4 Antagonist, L001, Suppresses Pancreatic Cancer Metastasis

Metastatic pancreatic cancer remains a major clinical challenge, emphasizing the urgent need for the exploitation of novel therapeutic approaches with superior response. In this study, we demonstrate that the aberrant activation of prostaglandin E2 (PGE2 ) receptor 4 (EP4) is a prometastatic signal in pancreatic cancer. To explore the therapeutic role of EP4 signaling, we developed a potent and selective EP4 antagonist L001 with single-nanomolar activity using a panel of cell functional assays. EP4 antagonism by L001 effectively repressed PGE2-elicited cell migration and the invasion of pancreatic cancer cells in a dose-dependent manner. Importantly, L001 alone or combined with the chemotherapy drug gemcitabine exhibited remarkably anti-metastasis activity in a pancreatic cancer hepatic metastasis model with excellent tolerability and safety. Mechanistically, EP4 blockade by L001 abrogated Yes-associated protein 1 (YAP)-driven pro-metastatic factor expression in pancreatic cancer cells. The suppression of YAP’s activity was also observed upon L001 treatment in vivo. Together, these findings support the notions that EP4–YAP signaling axis is a vital prometastatic pathway in pancreatic cancer and that EP4 inhibition with L001 may deliver a therapeutic benefit for patients with metastatic pancreatic cancer.

Novel tetrahydrobenzo[b]thiophen-2-yl)urea derivatives as novel α-glucosidase inhibitors: Synthesis, kinetics study, molecular docking, and in vivo anti-hyperglycemic evaluation

α-Glucosidase inhibitors, which can inhibit the digestion of carbohydrates into glucose, are one of important groups of anti-type 2 diabetic drugs. In the present study, we report our effort on the discovery and optimization of α-glucosidase inhibitors with tetrahydrobenzo[b]thiophen-2-yl)urea core. Screening of an in-house library revealed a moderated α-glucosidase inhibitors, 5a, and then the following structural optimization was performed to obtain more efficient derivatives. Most of these derivatives showed increased inhibitory activity against α-glucosidase than the parental compound 5a (IC50 of 26.71 ± 1.80 μM) and the positive control acarbose (IC50 of 258.53 ± 1.27 μM). Among them, compounds 8r (IC50 = 0.59 ± 0.02 μM) and 8s (IC50 = 0.65 ± 0.03 μM) were the most potent inhibitors, and showed selectivity over α-amylase. The direct binding of both compounds with α-glucosidase was confirmed by fluorescence quenching experiments. Kinetics study revealed that these compounds were non-competitive inhibitors, which was consistent with the molecular docking results that compounds 8r and 8s showed high preference to bind to the allosteric site instead of the active site of α-glucosidase. In addition, compounds 8r and 8s were not toxic (IC50 > 100 μM) towards LO2 and HepG2 cells. Finally, the in vivo anti-hyperglycaemic activity assay results indicated that compounds 8r could significantly decrease the level of plasma glucose and improve glucose tolerance in SD rats treated with sucrose. The present study provided the tetrahydrobenzo[b]thiophen-2-yl)urea chemotype for developing novel α-glucosidase inhibitors against type 2 diabetes.

THIENOCYCLIC COMPOUND AND SYNTHESIS METHOD THEREFOR AND APPLICATION THEREOF

Disclosed by the present invention are a thienocyclic compound represented by formula (I), a pharmaceutically acceptable salt or a hydrate thereof, a composition containing the thienocyclic compound, and a preparation method therefor. Further disclosed by

EP4 receptor antagonist and PD-1 inhibitor combined and used for treating cancer

The invention provides an EP4 receptor antagonist and a PD-1 inhibitor combined and used for treating cancer. The invention provides the product combination, including a first medicine composition (i)and a second medicine composition (ii), the first medic

ANTI-INFECTIVE 2-AMINOTHIOPHENES

2-Aminothiophene derivatives, uses of the same, and methods of making the same, are described.

CDK8 INHIBITORS AND USES THEREOF

The present invention provides methods of using compounds of formula I: and compositions thereof for the inhibition of CDK8, and the treatment of CDK8-mediated disorders.